ArticleCureus2025
Zoledronic Acid-Related Hypocalcemia and Renal Dysfunction in Oncology Patients: A Tertiary Care Experience.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Zoledronic acid, a bisphosphonate commonly used to manage bone metastases and malignancy-associated hypercalcemia in cancer patients, has proven clinical efficacy in preventing skeletal-related events. However, its use is associated with adverse effects, particularly hypocalcemia and renal dysfunction. Despite its widespread application, data from local cancer populations remain limited, which may impact the development of region-specific risk mitigation protocols. This study was conducted to assess the frequency of hypocalcemia and elevated serum creatinine levels in cancer patients treated with zoledronic acid at a tertiary care cancer hospital. Methodology This retrospective observational study was conducted at the Department of Oncology, Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, Pakistan. Medical records of 400 adult cancer patients treated with intravenous zoledronic acid between January 1 and December 31, 2024 were reviewed. After applying exclusion criteria, including baseline hypercalcemia and chronic kidney disease, 243-300 patients were included in the final analysis for calcium and creatinine outcomes. Data on demographics, baseline, and post-treatment serum calcium and creatinine levels were collected and analyzed using SPSS. Paired samples t-tests were used to assess statistical differences, with p<0.05 considered significant. Results Following treatment, the mean serum creatinine level rose from 0.714 mg/dL to 1.572 mg/dL (mean increase: 0.86 mg/dL, p<0.001), indicating a statistically and clinically significant decline in renal function. Similarly, mean corrected serum calcium dropped from 9.41 mg/dL to 8.52 mg/dL (mean decrease: 0.89 mg/dL, p<0.001), confirming a significant hypocalcemic effect. Approximately 29.4% of patients developed post-treatment creatinine levels >1.3 mg/dL, and 2.0% experienced calcium levels <7 mg/dL. Conclusion Zoledronic acid was associated with significant post-treatment increases in serum creatinine and decreases in calcium levels in cancer patients. These findings reinforce the need for routine renal and calcium monitoring, along with appropriate supplementation, to improve treatment safety and patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.